Pharvaris N.V. logo

Pharvaris N.V.

NASDAQ:PHVS

Overview | Financials
Company Name Pharvaris N.V.
Symbol PHVS
Currency USD
Price 18.77
Market Cap 1,010,139,459
Dividend Yield 0%
52-week-range 14.049 - 33
Industry Biotechnology
Sector Healthcare
CEO Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA
Website https://pharvaris.com

An error occurred while fetching data.

About Pharvaris N.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft

Related Stocks

Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

GOSS

1.17 USD

Kiniksa Pharmaceuticals, Ltd. logo

Kiniksa Pharmaceuticals, Ltd.

KNSA

21.21 USD

Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc.

RANI

3.7 USD

Inogen, Inc. logo

Inogen, Inc.

INGN

9.01 USD

Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc.

RLMD

4.06 USD

PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

PMVP

1.58 USD

Aveanna Healthcare Holdings Inc. logo

Aveanna Healthcare Holdings Inc.

AVAH

3.19 USD

Financials

Numbers are in millions USD

Numbers are in millions USD